Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Abbreviations T2DM: Type 2 Diabetes Mellitus GLP1: Glucagon-like peptide1 GIP: Glucose-dependent insulinotropic polypeptide HbA1c: Hemoglobin A1c GLP1RAs: Glucagon-like peptide1 receptor agonists GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP1R: Glucagon-like peptide1 receptor CVD: Cardiovascular Disease MACE: Major Adverse Cardiovascular Event HF: Heart Failure HFrEF: Heart Failure with Reduced Ejection Fraction HFpEF: Heart Failure with Preserved Ejection Fraction ASCVD: Atherosclerotic Cardiovascular Disease CVOTs: Cardiovascular Outcome Trials SA: Sinoatrial ICAM-1: Intercellular Adhesion Molecule 1 GDF15: Growth Differentiation Factor 15 CRP: C-reactive protein LPS: Lipopolysaccharide TLR4: Toll-like receptor 4 NLRP3: NOD-like receptor protein 3 TNF-: Tumor Necrosis Factor-alpha IL-1: Interleukin-1 beta IL-6: Interleukin-6 TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling BCAA: Branched-chain amino acids BCKA: Branched-chain ketoacids HOMA2-IR: Homeostasis Model Assessment of Insulin Resistance LDL: Low-Density Lipoprotein VLDL: Very Low-Density Lipoprotein BP: Blood Pressure References Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR et al
As well as following a healthy diet and exercise routine, getting enough sleep will help you to avoid weight gain
Many patients with diabetes spend months if not years finding the optimal medications that are tailored to their bodies to obtain adequate control of their blood sugar levels
